ILUMYA (tildrakizumab-asmn) is an injectable solution that contains an interleukin-23 (IL-23) antagoinst. ILUMYA is is administered as subcutaneous injection of 100mg at week 0, week 4 then every 12 weeks thereafter. ILUMYA is used to treat plaque psoriasis in patients who will benefit from systemic therapy (injection or pills), or phototherapy (UV light). Patients must be tested for tuberculosis (TB) before starting treatment with ILUMYA. ILUMYA can increase a patient’s risk for infections.
What are the ingredients in ILUMYA?
The active ingredient in ILUMYA is tildrakizumab-asmn.
How does ILUMYA work?
Tildrakizumab-asmn is a monoclonal antibody. It is a protein that binds to a specific receptor on interleukin-23 (a cytokine that is involved in inflammatory responses) and prevents IL-23 from binding with the IL-23 receptor. This action stops the interleukin from interacting with white blood cells and stops the cascade of reactions that lead to an inflammatory response. In people with plaque psoriasis, there is an overactive inflammatory response. ILUMYA is considered a maintenance therapy for plaque psoriasis and has been tested to be safe to use for at least a year.
What are the possible side effects of ILUMYA?
Many clinical trials evaluated the safety and efficacy of ILUMYA. The most common side effects experienced by those taking ILUMYA include:
Upper respiratory infections
Injection site reactions
This is not an exhaustive list of all potential side effects of ILUMYA. For more information, consult your doctor or healthcare provider. If you notice any new or worsening side effects, contact your doctor or healthcare provider immediately.
Things to note about ILUMYA
Before starting ILUMYA, talk with your doctor if you have any active or chronic infections. All patients who are going to be taking ILUMYA need to be evaluated for tuberculosis. If you are found to have tuberculosis, your doctor may treat you before starting ILUMYA. Patients receiving ILUMYA should not receive live vaccines.
Individuals who are allergic to ILUMYA or any of its ingredients should not use ILUMYA. Signs of an allergic reaction include, but are not limited to, the following:
Swelling of the face, eyelids, lips, mouth, tongue or throat
Skin rash or hives
Breathing difficulties or throat tightness
If you notice any signs of a potential allergic reaction, seek immediate medical attention. The most common hypersensitive reactions in patients using ILUMYA were hives and swelling.
Pregnant or nursing mothers should not use ILUMYA, as it is not known if the medication will impact a developing fetus or if ILUMYA is excreted through breast milk. ILUMYA has not been tested children, and should not be used on anyone under the age of 18. It is not known if ILUMYA can impact fertility. Please consult your physician if long-term fertility is a concern.
ILUMYA typically comes in a pre-filled syringe, which is administered by sub-cutaneous (under the skin) injection in the thighs, abdomen or upper arms by a healthcare provider. Each syringe contains 1 milliliter (mL) of ILUMYA, which is 100 milligrams (mg) of medication. The medication is stored at a refrigerated temperature but given at room temperature. Your doctor or healthcare team will confirm your dosage and administration schedule with you. It is important to follow their instructions exactly. If you take too much ILUMYA, seek medical attention immediately. You physician will monitor you and treat any symptoms accordingly. If you miss a dose, speak with your physician about making your dose up as soon as possible.1
For more information, read the full prescribing information of ILUMYA.1
Last reviewed: November 2018.
Ilumya prescribing information. Available at http://www.sunpharma.com/sites/default/files/pressreleases/ILUMYA%20US%20Prescribing%20Information.